Indolent Lymphoma: Can Rituximab Resolve the Watch-and-Wait Debate? -- Ross 102 (4): 220 -- JNCI Journal of the National Cancer Institute

Links shared publicly online about this topic.

  • 1,386
    total visits

Indolent Lymphoma: Can Rituximab Resolve the Watch-and-Wait Debate? -- Ross 102 (4): 220 -- JNCI Journal of the National Cancer Institute

jnci.oxfordjournals.org —

Indolent Lymphoma: Can Rituximab Resolve the Watch-and-Wait Debate? -- Ross 102 (4): 220 -- JNCI Journal of the National Cancer Institute

View full resource at jnci.oxfordjournals.org

Tags: Cancer, Lymphoma, Non-Hodgkin Lymphoma Medication, Rheumatoid Arthritis Medication, Rituxan, MabThera

  • Share

Most Recently Shared on February 12, 2010 at 9:18 pm By:

JNCI_Now J Nat'l Cancer Inst

JNCI news story: Indolent lymphoma: to treat or to watch and wait? Will rituximab resolve that debate? http://bit.ly/9UgIge

2 years ago...

Reply

Retweet

Favorite

Advertisement